EntryPoint Capital LLC Has $416,000 Stock Holdings in Xeris Biopharma Holdings, Inc. $XERS

EntryPoint Capital LLC grew its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 43.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 75,706 shares of the company’s stock after purchasing an additional 22,946 shares during the quarter. EntryPoint Capital LLC’s holdings in Xeris Biopharma were worth $416,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. R Squared Ltd lifted its stake in shares of Xeris Biopharma by 27.7% in the 1st quarter. R Squared Ltd now owns 15,730 shares of the company’s stock valued at $86,000 after purchasing an additional 3,410 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Xeris Biopharma by 4.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company’s stock worth $273,000 after acquiring an additional 3,447 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in Xeris Biopharma by 31.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company’s stock valued at $55,000 after acquiring an additional 3,847 shares during the period. Apollon Wealth Management LLC grew its stake in Xeris Biopharma by 19.8% in the first quarter. Apollon Wealth Management LLC now owns 24,160 shares of the company’s stock valued at $133,000 after acquiring an additional 4,000 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in Xeris Biopharma by 5.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 170,482 shares of the company’s stock valued at $578,000 after acquiring an additional 9,506 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on XERS shares. HC Wainwright started coverage on Xeris Biopharma in a research note on Tuesday, August 12th. They issued a “buy” rating and a $10.00 price objective for the company. Oppenheimer raised their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the company an “outperform” rating in a research note on Friday, May 9th. Finally, Wall Street Zen raised Xeris Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Xeris Biopharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.58.

Insider Buying and Selling

In related news, Director John Johnson sold 107,500 shares of Xeris Biopharma stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $7.32, for a total transaction of $786,900.00. Following the sale, the director directly owned 833,483 shares in the company, valued at approximately $6,101,095.56. This trade represents a 11.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kevin Mcculloch purchased 25,000 shares of the company’s stock in a transaction that occurred on Friday, June 13th. The shares were acquired at an average price of $4.38 per share, for a total transaction of $109,500.00. Following the completion of the acquisition, the insider directly owned 1,708,585 shares of the company’s stock, valued at $7,483,602.30. This trade represents a 1.48% increase in their position. The disclosure for this purchase can be found here. 6.47% of the stock is currently owned by corporate insiders.

Xeris Biopharma Stock Up 2.9%

Shares of NASDAQ:XERS opened at $7.57 on Thursday. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -36.05 and a beta of 0.65. Xeris Biopharma Holdings, Inc. has a 12-month low of $2.48 and a 12-month high of $7.79. The business’s 50 day moving average is $5.40 and its 200 day moving average is $4.79.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to analysts’ expectations of $64.58 million. As a group, equities research analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.